Debopriya Ghosh

Debopriya Ghosh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
DGDebopriya Ghosh
Debopriya Ghosh
JCJavier Cabrera
Javier Cabrera
Ensemble methods such as random forest works well on high-dimensional datasets. However, when the number of features is extremely large compared to the number of samples and the percentage of truly informative feature is very small, performance of traditional random forest decline significantly. To this end, we develop a novel approach that enhance the performance of traditional random forest by reducing the contribution of trees whose nodes are populated with less informative features. The proposed method selects eligible subsets at each node by weighted random sampling as opposed to simple random sampling in traditional random forest. We refer to this modified random forest algorithm as ”Enriched Random Forest”. Using several high-dimensional micro-array datasets, we evaluate the performance of our approach in both regression and classification settings. In addition, we also demonstrate the effectiveness of balanced leave-one-out cross-validation to reduce computational load and decrease sample size while computing feature weights. Overall, the results indicate that enriched random forest improves the prediction accuracy of traditional random forest, especially when relevant features are very few.

28 April 2023 in Marine Pollution Bulletin
Verified
Journal Article
Closed access
MKMehakdeep Kaur
Mehakdeep Kaur
DGDebopriya Ghosh
Debopriya Ghosh
SGShikha Guleria
Shikha Guleria
SAShailendra Kumar Arya
Shailendra Kumar Arya
SPSanjeev Puri
Sanjeev Puri
MKMadhu Khatri
Madhu Khatri

15 July 2025 in European Journal of Cancer
Verified
Journal Article
Open access
MAMariam Alexander
Mariam Alexander
YCYing Cheng
Ying Cheng
SLSe-Hoon Lee
Se-Hoon Lee
APANTONIO PASSARO
ANTONIO PASSARO
ASAlexander I. Spira
Alexander I. Spira
NLNatasha B. Leighl
Natasha B. Leighl
Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival. Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib. Resource utilization and participant-reported treatment satisfaction were evaluated at cycle (C) 1 day (D) 1 and C3D1. Time-in-chair was substantially lower for subcutaneous versus intravenous amivantamab (C1D1: median [range], 23 min or 0.4 h [0-12.0 h] vs 6.5 h [0-24.0 h]; C3D1: 35 min or 0.6 h [0-6.6 h] vs 3.4 h [0.5-9.0 h]), as were HCP time and participant time-in-room. More participants who received subcutaneous versus intravenous amivantamab reported feeling unrestricted (C1D1, 66 % vs 29 %; C3D1, 60 % vs 42 %) or unbothered (C1D1, 69 % vs 30 %; C3D1, 71 % vs 45 %) by administration, and reported gaining time for other activities (C1D1, 36 % vs 7 %; C3D1, 37 % vs 6 %). Few participants who received subcutaneous amivantamab reported moderate-to-very severe injection-site pain (C1D1, 14 %; C3D1, 16 %), swelling (C1D1, 5 %; C3D1, 6 %), or redness (C1D1, 5 %; C3D1, 6 %). Most subcutaneous amivantamab recipients preferred and were more satisfied with its administration versus historical experience with intravenous therapies and would recommend it. In PALOMA-3, subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, was a preferred option for patients who received amivantamab-lazertinib.

25 June 2020 in International Journal of Research in Hospital and Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
DGDebopriya Ghosh
Debopriya Ghosh
USUtpal Sanyal
Utpal Sanyal
AAAnup Adhikari
Anup Adhikari
Many controlled studies and neurological studies demonstrate that men and women are physically and mentally different. The purpose of this study is to find out whether there is any gender difference in respiratory capacity between trained athletes of both gender. This study was conducted at Kolkata (Serampore area), West Bengal, India. The subject was trained table tennis players of age group was 14 – 17 years. Significant differences have been found in height (cm), W/H ratio and PIF (l/s) between male and female lawn tennis players and all these values are significantly higher (P

11 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ASAnthony Scholer
Anthony Scholer
RMRebecca Marcus
Rebecca Marcus
MGMary Garland-Kledzik
Mary Garland-Kledzik
DGDebopriya Ghosh
Debopriya Ghosh
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
MGMelanie Goldfarb
Melanie Goldfarb
Taxonomy of hepatobiliary cancer (HBC) categorizes tumors by location or histopathology (tissue of origin, TO). Tumors originating from different TOs can also be grouped by overlapping genomic alterations (GA) into molecular subtypes (MS). The aim of this study was to create novel HBC MSs. Next-generation sequencing (NGS) data from the AACR-GENIE database were used to examine the genomic landscape of HBCs. Machine learning and gene enrichment analysis identified MSs and their oncogenomic pathways. Descriptive statistics were used to compare subtypes and their associations with clinical and molecular variables. Integrative analyses generated three MSs with different oncogenomic pathways independent of TO (n = 324; p < 0.05). HC-1 “hyper-mutated-proliferative state” MS had rapidly dividing cells susceptible to chemotherapy; HC-2 “adaptive stem cell-cellular senescence” MS had epigenomic alterations to evade immune system and treatment-resistant mechanisms; HC-3 “metabolic-stress pathway” MS had metabolic alterations. The discovery of HBC MSs is the initial step in cancer taxonomy evolution and the incorporation of genomic profiling into the TNM system. The goal is the development of a precision oncology machine learning algorithm to guide treatment planning and improve HBC outcomes. Future studies should validate findings of this study, incorporate clinical outcomes, and compare the MS classification to the AJCC 8th staging system.